June 13, 2018Open Access

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

TCTricia R. CottrellQueen's University ETElizabeth D. ThompsonJohns Hopkins University PFPatrick M. FordeJohns Hopkins University

Key Points

Key points are not available for this paper at this time.

Abstract

irPRC may be used to standardize pathologic assessment of immunotherapeutic efficacy. Long-term follow-up is needed to determine irPRC reliability as a surrogate for recurrence-free and overall survival.

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Cottrell et al. (Wed,) studied this question.

synapsesocial.com/papers/69df052cacbf09c32e61403b https://doi.org/https://doi.org/10.1093/annonc/mdy218

Demander à l'IA

Bookmark

View Full Paper